These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Fatal reactivation of occult hepatitis B virus infection after rituximab and chemotherapy in lymphoma: necessity of antiviral prophylaxis.
    Author: Zhang B, Wang J, Xu W, Wang L, Ni W.
    Journal: Onkologie; 2010; 33(10):537-9. PubMed ID: 20926902.
    Abstract:
    The anti-CD20 monoclonal antibody rituximab has been used extensively in the treatment of B-cell lymphoma. However, several studies reported hepatitis B virus (HBV) reactivation after rituximab administration. The majority of these cases have been described in chronic carriers of HBV, whereas reactivation in occult hepatitis B carriers is relatively rare. We report a fatal case of fulminant hepatitis B that occurred in a B-cell lymphoma patient with occult hepatitis B after rituximab-containing chemotherapy, which raised the necessity of antiviral prophylaxis in this setting.
    [Abstract] [Full Text] [Related] [New Search]